TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01291407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1,50mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1,60mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1,70mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
Study: NCT01291407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1,80mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
Study: NCT00544674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: F-18-fluoromisonidazole
Description: administered intravenously prior to PET scan
Study: NCT01439399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: association ketamine-lidocaine
Description: Ketamine-lidocaine group received a bolus of 1.5 mg.kg-1 of lidocaine and 0.5 mg.kg-1 of ketamine, a continuous infusion of 1.3 mg.kg-1.h-1 of lidocaine and 0.17 mg.kg-1.h-1 of ketamine was delivered followed by 0.9 mg.kg-1 of lidocaine with 0.08 mg.kg-1.h-1 of ketamine during 48 h, the dose of ketamine being reduced to 0.04 mg.kg-1.h-1 after the first 24 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group (C) received an equal volume of saline 0.9 % during 48 h.
Study: NCT02895074

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery
Description: A femtosecond laser (Alcon-Lensx, Alcon-Lensx, Inc.) was used in this study. After pupil dilation and topical anesthesia, the laser was docked to the eye using a curved contact lens to applanate the cornea. With the integrated OCT imaging system, the locations of the cornea and the anterior and posterior surfaces of the crystalline lens were determined. A 5.0-mm-diameter capsulotomy was created by scanning a cylindrical pattern and followed by lens fragmentation. The laser was disconnected, and the remainder of the surgery was performed as phacoemulsification (Infiniti® Vision System; Alcon, USA). Folded intraocular lenses (IOLs) were implanted in the capsular bags.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional phacoemulsification cataract surgery
Description: Phacoemulsification was performed through a temporal 3.2-mm clear corneal incision with the same machine and followed by IOLs implantation.
Study: NCT03319212

Intervention type: DEVICE
Group type: OTHER
Intervention: senofilcon A contact lenses
Description: Senofilcon A Daily Disposable Contact Lenses
Study: NCT00761722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Arm 1:~Cycle 1 (PK Phase) - Subjects will receive a single SC dose of 75 mg/m2 on Days 1 and 15. Single oral doses of a given formulation of azacitidine will be administered in increasing doses on Days 3 and 5, and at doses calculated to deliver 80% and 120% of the SC exposure, up to a maximum dose of 600 mg on Days 17 and 19.~Cycles 2 and beyond - (Treatment phase) Oral azacitidine will be administered in a dose calculated to deliver 100% of the SC exposure up to a maximum of 600 mg on days 1 - 7 of a 28 day cycle.~Arm 2:~All Cycles - Oral azacitidine will be administered a maximum of 600 mg on Days 1 - 7 of a 28 days cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Arm 1:~Cycle 1 (PK Phase) - Subjects will receive a single SC dose of 75 mg/m2 on Days 1 and 15. Single oral doses of a given formulation of azacitidine will be administered in increasing doses on Days 3 and 5, and at doses calculated to deliver 80% and 120% of the SC exposure, up to a maximum dose of 600 mg on Days 17 and 19.~Cycles 2 and beyond - (Treatment phase) Oral azacitidine will be administered in a dose calculated to deliver 100% of the SC exposure up to a maximum of 600 mg on days 1 - 7 of a 28 day cycle.~Arm 2:~All Cycles - Oral azacitidine will be administered a maximum of 600 mg on Days 1 - 7 of a 28 days cycle.
Study: NCT00718705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Josamycin
Description: josamycin with posology of 2 grams per day by oral way during 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with posology of 2 grams per day by oral way during 10 days
Study: NCT01653990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: oral dose of 400mg moxifloxacin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: moxifloxacin
Description: oral dose of 400mg moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin-placebo
Description: Oral dose of a pill of moxifloxacin-placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: moxifloxacin-placebo
Description: Oral dose of a pill of moxifloxacin-placebo
Study: NCT01895959

Intervention type: DRUG
Group type: OTHER
Intervention: Euflexxa
Description: Euflexxa will be injected weekly for 3 consecutive weeks on the knee joint.

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI of the knee will be acquired during baseline (a week prior to the treatment), follow up visit 1 (1 week after treatment) and follow up visit 2 (3 months after treatment).
Study: NCT00397436

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UV Irradiation
Description: UV irradiation
Study: NCT03116256

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Very low calorie diet (VLCD)
Description: All participants (including exercise group) will be using full daily meal replacement during the 6-week interventional period. The total meal supplement is 600 kcal/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Very low calorie diet (VLCD)
Description: All participants (including exercise group) will be using full daily meal replacement during the 6-week interventional period. The total meal supplement is 600 kcal/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Very low calorie diet (VLCD)
Description: All participants (including exercise group) will be using full daily meal replacement during the 6-week interventional period. The total meal supplement is 600 kcal/day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High intensity interval training (HIIT)
Description: Participants in this group will be having HIIT session three times per week under close medical supervision. This involves 60 sec high intensity cycling at 95-125% Watt Max, with 90s recovery, repeated 5 times, with 2 minutes warm up and cool down.
Study: NCT03792672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-653 placebo-matching tablets.
Study: NCT03116256

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance exercise training (RET)
Description: The exercise format will be 2 sets of 12 repetitions at 70% 1-RM for each resistance regime, with 1-2 minutes rest between sets after a prescribed warm-up 3 sessions/week. The resistance regimes are: (3 upper body)chest press, latissimus pull down, seated lever row; (3 lower body) leg extension, leg curl, leg press. Participants will be alternating between upper and lower body exercise during each training session.
Study: NCT05002179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Echinaforce Chewable tablets
Description: Preventive treatment: 3X2 EC tablets daily during 2 + 2 months of prevention after run-in of 1 week and intermittent treatment break of 1 week without treatment + 1 month of voluntary follow-up prevention.~Acute treatment: 5 X 2 EC tablets daily for max. 10 days per individual vRTI or until symptom resolution.
Study: NCT02728466

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flavanol and procyanidin supplement
Description: Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing flavanols (monomers) and procyanidins (dimers to decamers)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Procyanidin-containing supplement
Description: Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing procyanidins (dimers to decamers)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: control supplement deprived of flavanols and procyanidins
Description: Placebo comparator: flavanol and procyanidin deprived supplement Sustained intake (2x daily over 1 month) of a macro-and micronutrient matched supplement
Study: NCT01135095

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-dose imaging
Description: The study is designed to assess the validity of a low dose (\~5mSv) Tc99m one day protocol using D-SPECT standard protocol as the comparators.~D-SPECT cardiac scanner the D-SPECT system uses a solid-state detector, made of an alloy of Cadmium, Zinc, and Telluride, eliminating the need for thick crystals and large photomultiplier tubes. As a result, the system is significantly miniaturized, and ergonomically optimized to both user and patient
Study: NCT01052077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: Tablets, Oral, 1 - 3 mg OPC-34712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02895074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropicamide
Description: After pupil dilation, 1 drop of tropicamide (0.5%) was applied every 15 minutes for 3 applications

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropicamide
Description: After pupil dilation, 1 drop of tropicamide (0.5%) was applied every 15 minutes for 3 applications

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proparacaine hydrochloride
Description: topical anesthesia with proparacaine hydrochloride (0.5%) was applied.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proparacaine hydrochloride
Description: topical anesthesia with proparacaine hydrochloride (0.5%) was applied.
Study: NCT02579889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DDD+CLS
Description: Device will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DDD(R)
Description: Device will be programmed in a dual-chamber DDD(R) pacing mode with the Closed Loop Stimulation (CLS) function OFF
Study: NCT03490006

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: A relatively recent alternative to the paravertebral block is the thoracic erector spinae plane block, which involves the ultrasound-guided injection of local anesthetic into the interfascial plane deep to the erector spinae muscle at the level of the transverse process. It results in a loss of somatic sensory sensation across multiple unilateral dermatomes due to local anesthetic mediated blockade of the dorsal and ventral rami of the spinal nerve roots. It is increasingly being used due to ease of placing the block and a perception of greater safety. It has been shown to provide pain relief from rib fractures, thoracotomy, and chronic neuropathic pain of the chest wall. However, to date, erector spinae plane block has not been compared with paravertebral block in regards to analgesia with mastectomy surgery, which has been extensively studied.
Study: NCT01052077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ADT
Study: NCT03408964

Intervention type: OTHER
Intervention: biological samples collection and analysis
Description: Participants to the study will be assigned to 4 cohorts according to the stage of disease and planned antitumor treatment at time of study entry; they will be followed up and sampled according to a defined time schedule

Intervention type: OTHER
Intervention: biological samples collection and analysis
Description: Participants to the study will be assigned to 4 cohorts according to the stage of disease and planned antitumor treatment at time of study entry; they will be followed up and sampled according to a defined time schedule

Intervention type: OTHER
Intervention: biological samples collection and analysis
Description: Participants to the study will be assigned to 4 cohorts according to the stage of disease and planned antitumor treatment at time of study entry; they will be followed up and sampled according to a defined time schedule

Intervention type: OTHER
Intervention: biological samples collection and analysis
Description: Participants to the study will be assigned to 4 cohorts according to the stage of disease and planned antitumor treatment at time of study entry; they will be followed up and sampled according to a defined time schedule
Study: NCT03490006

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral Block
Description: Paravertebral block is a classic regional anesthesia technique that has been in use for over 100 years. It is performed by the injection of local anesthetic into the space between the costotransverse ligament and parietal pleura resulting in blockade of ipsilateral intercostal nerves. It results in a loss of somatic sensation over multiple unilateral dermatomes.
Study: NCT03408964

Intervention type: OTHER
Intervention: biological samples collection and analysis
Description: Participants to the study will be assigned to 4 cohorts according to the stage of disease and planned antitumor treatment at time of study entry; they will be followed up and sampled according to a defined time schedule
Study: NCT03400748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF Ablation
Description: The intervention consists of a bronchoscopic approach to ablate lung tumors with radio-frequency energy.
Study: NCT01818999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IXABEPILONE
Description: injection
Study: NCT03514966

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Position change group
Description: Right after ingesting 5 g dimethicone mixed with 100 ml water, subjects in the position change group will be instructed to repeatedly change the body position according to a pre-specified protocol for a period of 15 min: in the order of supine to the left lateral position to prone, left lateral, supine, right lateral, and repeat last four positions twice, each for 1 min; finally supine for 1 min. Thirty and 40 min after dimethicone administration, subjects in both groups will additionally take 200 ml and 800 ml water, respectively before undergoing MCE examination.
Study: NCT03953326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HeartPhone app
Description: Evaluative conditioning (temporally distributed micro-doses presented upon activation of smartphone screen)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: Endothelium-dependent vasodilation is tested with the localized delivery of the neurotransmitter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside
Description: Endothelium-independent vasodilation is tested with the localized delivery of the nitric oxide donor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Arginine, N2-((4-Methylphenyl)Sulfonyl)-, Methyl Ester
Description: This nitric oxide inhibitor is continuously given during the localized delivery of the endothelium-dependent agonist acetycholine.
Study: NCT02407639

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CO2
Description: gas

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: air
Description: air
Study: NCT00317694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fermagate
Description: Film coated tablet 500mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration, film coated tablet, 0mg
Study: NCT02481869

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Arthrocentesis/PRP
Description: PRP (n=20): single intra-articular injection of 5 ml of a leukocyte-reduced platelet rich plasma (ACP, Arthrex, Naples, FL) at the time of closed reduction and initial stabilization using ankle-spanning external fixation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Arthrocentesis/Saline
Description: Control (n=20): single intra-articular injection of 5 ml of sterile 0.9% saline at the time of closed reduction and initial stabilization using ankle-spanning external fixation
Study: NCT04836845

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Focus extracorporeal shock wave therapy
Description: Focus extracorporeal shock wave therapy, device: Electronica, Pagani, Italy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radial extracorporeal shock wave therapy
Description: Radial extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
Study: NCT03872973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Training
Description: The experimental group will perform neuromuscular exercise for 6 weeks.~The other experimental group will perform neuromuscular exercises with strobe glasses.
Study: NCT04836845

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham extracorporeal shock wave therapy
Description: Sham extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
Study: NCT04560387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician-lead complex program of weight-reducing interventions
Description: A structured motivational and goal directed program will be used for weight reduction involving physicians, nutritionists, educators and physiotherapists. Initially, based on the input data provided by the patient an individual nutritional plan will be designed with the aim of reducing caloric intake by 10%. Low-intensity aerobic exercise for 30 min will be prescribed 3-times a week with the aim of increasing the frequency to 5-times a week and participants will be offered the possibility to participate in regular physiotherapist-lead group exercises. Patients will be required to maintain a diet and physical activity diary. Regular reviews will be scheduled every 3-6 months according to the actual weight loss.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery - sleeve gastrectomy
Description: Bariatric surgery will be performed based on actual medical indication and independently of patient's participation in the study. Sleeve gastrectomy was selected as the currently most frequent restrictive type of bariatric surgery with a proven efficacy on weight reduction, metabolic status and low-grade inflammation
Study: NCT01818999

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: STEREOTACTIC BODY RADIATION THERAPY
Description: SBRT will begin between 1 and 5 weeks after the initiation of Ixabepilone. Patients will receive one, three, or five fractions.
Study: NCT03792672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-653 placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-653 placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-653 placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-653 placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-653 placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine intravenous infusion.
Study: NCT02542787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSN16R
Description: Small molecule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: dummy tablet
Study: NCT03792672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine intravenous infusion.
Study: NCT03039699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergoferon

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03792672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine intravenous infusion.
Study: NCT00453999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peramivir 200 mg
Description: Peramivir (200 mg in 100 mL of solution) intravenous infusion (over 15 minutes) and an orally administered oseltamivir placebo suspension (6.25 mL) treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peramivir 400 mg
Description: Peramivir (400 mg in 100 mL of solution ) intravenous infusion (over 15 minutes) and an orally administered oseltamivir placebo suspension (6.25 ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Placebo peramivir infusion (over 15 minutes) and a 75-mg dose of oseltamivir suspension (6.25 mL)
Study: NCT03778151

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION
Description: daily treatment session of REPETITIVE TRANSCRANIAL MAGNETIC STIMULATIO will be applied over precuneus for 20 minutes of consecutive blocks of 20Hz pulses for two seconds followed by 28 seconds of no stimulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION
Description: daily treatment session of REPETITIVE TRANSCRANIAL MAGNETIC STIMULATIO will be applied over precuneus for 20 minutes of consecutive blocks of 20Hz pulses for two seconds followed by 28 seconds of no stimulation.
Study: NCT03087656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: Intravenous Ceftriaxone will be given during the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: Oral Levofloxacin will be given for 3 days after the procedure.
Study: NCT00802412

Intervention type: DRUG
Group type: OTHER
Intervention: Topiramate
Description: Topiramate will be titrated over 5 weeks to a maximum dosage of 200 mg according to the following schedule: 25mg daily for days 1-7, 50mg daily for days 8-14, 75mg daily for days 15-21, 100mg daily for days 22-28, 150mg daily for days 29-35, 200mg daily for days 36-42. Maximum dosage will be maintained for 6 weeks, followed by a one-week taper-off period (100mg daily for 4 days and 50mg daily for 3 days).